Get the Stockscreener App
2.17
11.28%
0.22
Pre-market:
1.95
-0.22
-10.14%
Okyo Pharma Limited stock is traded at $2.17, with a volume of 349.79K.
It is up +11.28% in the last 24 hours and down -24.65% over the past month.
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
See More
Previous Close:
$1.95
Open:
$1.94
24h Volume:
349.79K
Relative Volume:
1.74
Market Cap:
$88.00M
Revenue:
-
Net Income/Loss:
$-13.27M
P/E Ratio:
-13.23
EPS:
-0.164
Net Cash Flow:
$-7.70M
1W Performance:
+14.21%
1M Performance:
-24.65%
6M Performance:
-26.75%
1Y Performance:
+99.08%
1-Day Range:
$1.90
$2.2294
1-Week Range:
$1.82
$2.28
52-Week Range:
$1.03
$3.349
Okyo Pharma Limited Stock (OKYO) Company Profile
Compare OKYO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
2.17 | 79.08M | 0 | -13.27M | -7.70M | -0.164 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-08-25 | Initiated | B. Riley Securities | Buy |
Okyo Pharma Limited Stock (OKYO) Latest News
OKYO Pharma prices public offering at $1.85/share to raise up to $20M - MSN
OKYO Pharma Limited Prices Public Offering of Ordinary Shares to Raise Approximately $20 Million - Quiver Quantitative
Okyo Pharma Ltd Announces Pricing Of $20 Million Public Offering Of Ordinary Shares - TradingView
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares - Yahoo Finance Singapore
OKYO Pharma Prices Public Offering at $1.85 per Share - Intellectia AI
Okyo Pharma announces ordinary shares offering, no amount given - TipRanks
OKYO Pharma launches underwritten public offering of ordinary shares - MSN
OKYO Pharma Launches Public Offering to Fund Next Phase of Corneal Pain Drug Development - TipRanks
OKYO Pharma Announces Public Offering of Ordinary Shares - Bitget
OKYO Pharma Announces Public Offering of Ordinary Shares - Benzinga
OKYO Pharma Appoints Flavio Mantelli, MD, as Chief Medical Officer - VisionMonday.com
Volatility Watch: Will JBG SMITH Properties outperform tech stocksJuly 2025 Trade Ideas & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Small cap wrap: OKYO Pharma, Arizona Gold & Silver, Standard Uranium, C3 Metals… - Proactive financial news
OKYO Pharma appoints Leerink Partners as sales agent for ATM equity offering - Proactive financial news
OKYO Pharma Switches ATM Equity Facility to Leerink Partners to Support Urcosimod Push - TipRanks
OKYO Pharma transitions ATM equity offering to Leerink Partners as sales agent - Investing.com
OKYO Pharma Limited Transitions ATM Equity Offering to Leerink Partners LLC for Enhanced Capital Access - Quiver Quantitative
OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners - marketscreener.com
OKYO Pharma taps Leerink to raise cash for eye pain treatments - Stock Titan
Is OKYO Pharma Limited a turnaround storyJuly 2025 Snapshot & Low Drawdown Trading Techniques - mfd.ru
OKYO Pharma Launches $50 Million At-the-Market Share Offering With Leerink Partners - TipRanks
OKYO Pharma appoints former Dompé CMO Flavio Mantelli to lead NCP program By Investing.com - Investing.com South Africa
OKYO Pharma appoints former Dompé CMO Flavio Mantelli to lead NCP program - Investing.com Nigeria
OKYO Pharma appoints Flavio Mantelli as chief medical officer - Proactive financial news
OKYO Pharma Hires Oxervate Veteran Flavio Mantelli as Chief Medical Officer to Drive Urcosimod Program - TipRanks
OKYO Pharma Strengthens World Class Leadership Team with - GlobeNewswire
OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer - Finviz
What are OKYO Pharma Limited’s growth leversJuly 2025 Analyst Calls & Consistent Profit Trade Alerts - mfd.ru
Published on: 2026-02-04 02:26:16 - baoquankhu1.vn
OKYO Pharma’s neuropathic corneal pain study greenlit by FDAICYMI - Proactive financial news
OKYO Pharma to present urcosimod NCP study results at ASCRS meeting - Investing.com Nigeria
OKYO Pharma Advances Urcosimod With Positive Interim Results and FDA Alignment on Phase 2b/3 NCP Trial - TipRanks
Small cap wrap: OKYO Pharma, NEXE Innovations, Delivra Health Brands… - Proactive Investors
OKYO Pharma to present urcosimod NCP study results at ASCRS meeting By Investing.com - Investing.com South Africa
OKYO Pharma to present urcosimod Phase 2 results at ASCRS 2026 annual meeting - Proactive financial news
OKYO Pharma’s Urcosimod Phase 2 Data Accepted for Presentation at 2026 ASCRS Meeting - TipRanks
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting - The Manila Times
OKYO Pharma's Urcosimod Abstract Accepted for Presentation at 2026 ASCRS Annual Meeting - Quiver Quantitative
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study - GlobeNewswire
What is OKYO Pharma Limited s revenue forecast2025 Historical Comparison & Weekly Stock Performance Updates - mfd.ru
H.C. Wainwright reiterates Buy rating on OKYO Pharma stock with $7 price target - Investing.com Canada
H.C. Wainwright reiterates Buy rating on OKYO Pharma stock with $7 price target By Investing.com - Investing.com Nigeria
Day Trade: What drives CHEFs stock priceJuly 2025 Opening Moves & Safe Entry Momentum Tips - baoquankhu1.vn
OKYO Pharma receives FDA alignment on Phase 2b/3 trial for NCP treatment By Investing.com - Investing.com South Africa
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update - MarketBeat
OKYO Pharma clears key FDA meeting for Urcosimod Phase 2b/3 Trial - Proactive financial news
Market movers: AT&T, Okyo Pharma, Starbucks, Texas Instruments... - Proactive Investors
OKYO Pharma stock rises after FDA confirms Phase 2b/3 trial design - Investing.com UK
OKYO Pharma stock rises after FDA confirms Phase 2b/3 trial design By Investing.com - Investing.com Nigeria
OKYO Pharma reports successful FDA meeting on urcosimod clinical trial By Investing.com - Investing.com Nigeria
Okyo Pharma Limited Stock (OKYO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):